Immune cell army targets Hard-to-Treat lymphoma
Disease control
Not yet recruiting
This early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) to help the body fight the…
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated May 13, 2026 16:01 UTC